Acceleron And Celgene Expand Anemia Collaboration With Second Compound
This article was originally published in The Pink Sheet Daily
Executive Summary
The two companies will split development costs for ACE-536 in anemia-related conditions, and Acceleron will hold North American co-promotion rights.
You may also be interested in...
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2011
Biopharma financing dropped in Q3 2011 to $1.3 billion, down from $6.3 billion in Q2. There were 20 M&A deals that totaled $30.9 billion, attributed mainly to the $27.7 million merger of PBMs Express Scripts and Medco. Almost a quarter of the alliances penned were for preclinical assets.
Celgene Partners With Acceleron On Novel Bone Forming Compound
$997 million deal will includes ACE-011 for cancer-related bone loss and other discovery compounds.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.